Results 271 to 280 of about 759,881 (390)

Pain Management with Natural Products: Neurophysiological Insights. [PDF]

Int J Mol Sci
Takeda M, Sashide Y.
europepmc   +1 more source

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis

Arthritis &Rheumatology, EarlyView.
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley   +1 more source

Propofol Total Intravenous Anesthesia for Pediatric Proton Radiotherapy and Its Effect on Patient Outcomes. [PDF]

Cancers (Basel)
Owusu-Agyemang P, Mani J, Idowu T, Zavala A, Tsai J, Kapoor R, Idowu O, Galdamez Melara J, Muraleedharan P, Francis C, Feng L, Cata J.   +11 more
europepmc   +1 more source

Time‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study

Arthritis &Rheumatology, EarlyView.
Objective The objective of this study was to investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods This multicenter cohort study was designed to emulate a target trial that studied 296 patients with ...
Yun Kyu Kim, Jeffrey R. Curtis, Se Rim Choi, Jina Yeo, Min Jung Kim, Yun Jong Lee, Eun Bong Lee, Jun Won Park   +7 more
wiley   +1 more source

Reducing carbon, enhancing care: the future of sustainable medicine. [PDF]

Front Pharmacol
Provenzani A, Como M, Martucci G.
europepmc   +1 more source

Effect of different doses of intravenous dexmedetomidine as an adjunct to the serratus anterior plane block in patients undergoing modified radical mastectomy: a randomized controlled trial. [PDF]

Ann Med
Huang L, Zhao S, Zhu W, Zhu X, Pan L, Wang Q, Shi K.   +6 more
europepmc   +1 more source

Aberrant Glycosylation of IgG in Children With Active Lupus Nephritis Alters Podocyte Metabolism and Causes Podocyte Injury

Arthritis &Rheumatology, EarlyView.
Objective Podocytes are integral to the maintenance of the glomerular filtration barrier. Their injury results in proteinuria and disease progression in lupus nephritis (LN). Aberrant IgG glycosylation drives podocyte injury in LN and leads to cytoskeletal rearrangement, motility changes, and decreased nephrin production.
Rhea Bhargava, Rohit Upadhyay, Cong Zhao, Prasad Katakam, Scott Wenderfer, Jing Chen, Hua He, Richard Cummings, Maria G. Tsokos, George C. Tsokos   +9 more
wiley   +1 more source

From neurotoxicity to neuroprotection: Rethinking GABA_AR-targeting anesthetics. [PDF]

Cell Biol Toxicol
Li Y, Yang H, Liu L, Jiang L, Xie P, Wang X, Cong X, Zhu R, Lu Z, Sun M, Zhang J.   +10 more
europepmc   +1 more source

Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies

Arthritis &Rheumatology, EarlyView.
Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to 3 years; all patients received mycophenolate mofetil and low‐dose glucocorticoids.
Brad H. Rovin, Clarissa Cassol, Samir V. Parikh, Amit Saxena, Neil Solomons, Vanessa Birardi, Ernie Yap, Clint W. Abner, David R. W. Jayne, Robert B. Huizinga   +9 more
wiley   +1 more source

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti–double‐stranded DNA (anti‐dsDNA) is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA ...
Hugo J. van Dooren, Mieke van Schaik, Annemarie L. Dorjée, Eline J. Arends, Meggan Mackay, Laura Cooney, David A. Fox, David Wofsy, Dawn Smilek, Cynthia Aranow, Maria Dall'Era, Tom W. J. Huizinga, Cees van Kooten, René E. M. Toes, Betty Diamond, Y. K. Onno Teng, Jolien Suurmond   +16 more
wiley   +1 more source